PEPTIDEREPORT

FDA · Guidance

FDA finalizes interim policy for 503A compounding with bulk drug substances

FDA published final guidance describing its interim regulatory policy for certain bulk drug substances used by state-licensed pharmacies and physicians under section 503A.

Final guidance legal stageJan 6, 2025 record dateUnited States jurisdiction
Open the primary-source record

Record status

Final guidance

Agency
U.S. Food and Drug Administration
Action
Final guidance
Stage
Final guidance
Last verified
Jul 10, 2026

Source-backed timeline

Status history

  1. Final guidance publishedSource

Editorial boundary: Peptide Report summarizes the public source and preserves its procedural stage. This page does not convert an allegation, proposal, advisory discussion, or warning into a final legal conclusion.

Back to all Regulatory Watch records